Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares.

The company announced top-line results from the SIGNAL-AA Phase IIa signal finding clinical trial evaluating bempikibart (ADX ...

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of ...